1. Scrip
  2. >>Business
  3. >>Financing

China Biotechs Hang Onto Smaller VC/PE Funding Deals In September, October

 
• By Dexter Jie Yan

LaNova Medicines, as well as other Chinese RNA interference specialists and developers of stem cell-based therapies, were among those securing new funds from venture capital and private equity firms over the past few months.

funding
Chinese biotechs saw smaller-sized funding deals backed by venture capital and private equity firms in September and October. • Source: Shutterstock

Chinese biotechs continued to secure smaller-sized fundings backed by venture capital and private equity firms in September and October, with the single largest fundraising standing at $42m.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Scrip

Merck KGaA Moves Closer To Sealing SpringWorks Buy

 
• By Kevin Grogan

The German group could pay $3.5bn to get hold of the US firm and its two approved products.

In Brief: Mosaic Gains Two Clinical-Stage Oncology Assets From Astex

 
• By Sushmita Panda

Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.